Abstract

Novel compounds have been developed that (in many cases) inhibit cholinesterases and concomitantly interact with at least one further pharmacological target, such as 5-HT3 or H3 receptors. But also enzymes like monoamine oxidase and the serotonin transporter have been targeted. Hybrid molecules can also incorporate antioxidant or neuronal Ca2+- channel-blocking structures.

Keywords: Hybrid molecules, Multiple ligands, AChE inhibitors, Serotonin transporter (SERT), monoamine oxidase (MAO), lipoic acid, 5-HT3 receptor, Ca2+-channel blockers